JP2014531442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531442A5 JP2014531442A5 JP2014530369A JP2014530369A JP2014531442A5 JP 2014531442 A5 JP2014531442 A5 JP 2014531442A5 JP 2014530369 A JP2014530369 A JP 2014530369A JP 2014530369 A JP2014530369 A JP 2014530369A JP 2014531442 A5 JP2014531442 A5 JP 2014531442A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- polypeptide
- coli
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 53
- 230000002163 immunogen Effects 0.000 claims description 46
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000001708 Protein Isoforms Human genes 0.000 claims description 11
- 108010029485 Protein Isoforms Proteins 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 6
- 239000012619 Butyl Sepharose® Substances 0.000 claims description 6
- 102000004895 Lipoproteins Human genes 0.000 claims description 6
- 108090001030 Lipoproteins Proteins 0.000 claims description 6
- 239000000688 bacterial toxin Substances 0.000 claims description 6
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000000369 enteropathogenic effect Effects 0.000 claims description 2
- 230000007717 exclusion Effects 0.000 claims description 2
- 101150023725 gspK gene Proteins 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000004572 zinc-binding Effects 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201115906A GB201115906D0 (en) | 2011-09-14 | 2011-09-14 | Escherichia coli vaccine combination |
| GB1115906.8 | 2011-09-14 | ||
| GB1213251.0 | 2012-07-25 | ||
| GBGB1213251.0A GB201213251D0 (en) | 2012-07-25 | 2012-07-25 | Escherichia coli vaccine combination |
| PCT/IB2012/054825 WO2013038385A2 (en) | 2011-09-14 | 2012-09-14 | Escherichia coli vaccine combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014531442A JP2014531442A (ja) | 2014-11-27 |
| JP2014531442A5 true JP2014531442A5 (enExample) | 2015-10-15 |
Family
ID=47116137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530369A Pending JP2014531442A (ja) | 2011-09-14 | 2012-09-14 | Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9511130B2 (enExample) |
| EP (1) | EP2755994A2 (enExample) |
| JP (1) | JP2014531442A (enExample) |
| CN (1) | CN103930436A (enExample) |
| WO (1) | WO2013038385A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| CN109234418B (zh) * | 2018-11-20 | 2021-08-13 | 湖南中净生物科技有限公司 | 一种鉴别猪肺炎支原体野毒株和疫苗株的引物、试剂盒和方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| EP1035867A1 (en) | 1997-12-02 | 2000-09-20 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
| BR9907884A (pt) | 1998-02-12 | 2000-10-24 | American Cyanamid Co | Composição de vacina, processos para gerar uma resposta imune em um antìgeno pneumocócico, para aumentar resposta de ifn-gama em uma vacina pneumocócica, e para gerar anticorpos de fixação complementar para uma resposta protetora a um patógeno, composição imunogênica, e, processo para gerar uma resposta imune em um antìgeno meningocócico |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| PT1372708E (pt) | 2001-02-13 | 2008-09-29 | Us Gov Sec Army | Vacina para imunização transcutânea |
| JP2004529906A (ja) | 2001-03-19 | 2004-09-30 | イオマイ コーポレイシヨン | 経皮的免疫賦活 |
| US20040191170A1 (en) | 2001-04-03 | 2004-09-30 | Mond James J. | Animal model for enteric pathogens |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| GB0123580D0 (en) | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005103073A2 (en) | 2004-04-27 | 2005-11-03 | Intercell Ag | Td antigens |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| ES2595363T3 (es) | 2005-02-18 | 2016-12-29 | J. Craig Venter Institute, Inc. | Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli |
| ITMI20081249A1 (it) * | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| WO2011004263A2 (en) * | 2009-07-07 | 2011-01-13 | Novartis Ag | Conserved escherichia coli immunogens |
| HRP20141270T1 (xx) * | 2009-07-16 | 2015-03-13 | Novartis Ag | Detoksificirani imunogeni escherichie coli |
| WO2011080595A2 (en) | 2009-12-30 | 2011-07-07 | Novartis Ag | Polysaccharide immunogens conjugated to e. coli carrier proteins |
-
2012
- 2012-09-14 EP EP12780542.2A patent/EP2755994A2/en not_active Withdrawn
- 2012-09-14 WO PCT/IB2012/054825 patent/WO2013038385A2/en not_active Ceased
- 2012-09-14 US US14/344,892 patent/US9511130B2/en not_active Expired - Fee Related
- 2012-09-14 JP JP2014530369A patent/JP2014531442A/ja active Pending
- 2012-09-14 CN CN201280055664.7A patent/CN103930436A/zh active Pending
-
2016
- 2016-12-05 US US15/369,405 patent/US10105429B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517489A5 (enExample) | ||
| CN106456723B (zh) | 采用精氨酸酶i调节免疫系统的方法和组合物 | |
| JP2016539946A5 (enExample) | ||
| JP2013534532A5 (enExample) | ||
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| JP2015522576A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| Zhang et al. | Tongue sole (Cynoglossus semilaevis) prothymosin alpha: cytokine-like activities associated with the intact protein and the C-terminal region that lead to antiviral immunity via Myd88-dependent and-independent pathways respectively | |
| US9169477B2 (en) | Compositions and methods for immunization against bacteria expressing a carbapenemase | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2013520487A5 (enExample) | ||
| JP2015500827A5 (enExample) | ||
| RU2012107993A (ru) | Полипептиды porhyromonas gingivalis | |
| JP2016504993A5 (enExample) | ||
| JP2015505831A5 (enExample) | ||
| Menheniott et al. | STAT3: a critical component in the response to Helicobacter pylori infection | |
| JP2018529661A5 (enExample) | ||
| WO2014145357A2 (en) | Improved methods of use for recombinant human secretoglobins | |
| Schülke et al. | Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC | |
| Yue et al. | Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis | |
| US8741302B2 (en) | Polypeptide derived from Enterococcus and its use for vaccination | |
| JP2009519025A5 (enExample) | ||
| CN106380510B (zh) | 鲍式不动杆菌的新靶标 |